These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10367667)

  • 1. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans.
    Mordenti J; Thomsen K; Licko V; Chen H; Meng YG; Ferrara N
    Toxicol Pathol; 1999; 27(1):14-21. PubMed ID: 10367667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
    Presta LG; Chen H; O'Connor SJ; Chisholm V; Meng YG; Krummen L; Winkler M; Ferrara N
    Cancer Res; 1997 Oct; 57(20):4593-9. PubMed ID: 9377574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
    Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
    J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
    Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
    Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.
    Borgström P; Hillan KJ; Sriramarao P; Ferrara N
    Cancer Res; 1996 Sep; 56(17):4032-9. PubMed ID: 8752175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
    Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
    J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
    Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
    Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
    Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
    Borgström P; Bourdon MA; Hillan KJ; Sriramarao P; Ferrara N
    Prostate; 1998 Apr; 35(1):1-10. PubMed ID: 9537593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P; Gold DP; Hillan KJ; Ferrara N
    Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of antibody against vascular endothelial growth factor on tumor growth].
    Wang G; Wang N; Liu T
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):163-6. PubMed ID: 10920886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
    Asano M; Yukita A; Matsumoto T; Hanatani M; Suzuki H
    Hybridoma; 1998 Apr; 17(2):185-90. PubMed ID: 9627059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
    Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.
    Matsumoto K; Konno H; Tanaka T; Baba M; Kanai T; Kamiya K; Ohba K; Nakamura S
    Jpn J Cancer Res; 2000 Jul; 91(7):748-52. PubMed ID: 10920283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis.
    Wang G; Dong Z; Xu G; Yang Z; Shou C; Wang N; Liu T
    J Cancer Res Clin Oncol; 1998; 124(11):615-20. PubMed ID: 9860290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.